Evaluation of Nivolumab Use and Factors related to Treatment Outcomes in a Cancer Center of a Top Tier General Hospital
Open Access
- 30 June 2018
- journal article
- Published by The Korean College of Clinical Pharmacy in Korean Journal of Clinical Pharmacy
- Vol. 28 (2), 88-94
- https://doi.org/10.24304/kjcp.2018.28.2.88
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2017
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals Of Oncology, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- ASHP Guidelines on Medication-Use EvaluationAmerican Journal of Health-System Pharmacy, 1996